PDCD1 and melanoma: Pembrolizumab (pembro) and nivolumab, two human IgG4 anti-PD-1 checkpoint inhibitor antibodies, were the first PD-1-targeted, FDA-approved therapies for refractory and unresectable melanoma [23,28,29].